Andelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular Junction
Ohio Pen/10306167

COLUMBUS, Ohio, Aug. 21, 2025 ~ As a leading and patient-focused Contract Development and Manufacturing Organization (CDMO), Andelyn Biosciences, Inc. has announced a new partnership with Amplo Biotechnology, a pioneer in adeno-associated virus (AAV) regenerative medicines for neuromuscular junction (NMJ) disorders. This collaboration will allow for the scalable manufacturing of clinical-grade AAV material, utilizing Andelyn's suspension AAV Curator® platform.

NMJ disorders are conditions that affect the neuromuscular junction, resulting in muscle weakness and potentially life-threatening complications. These diseases are typically diagnosed in early childhood but can also manifest in adolescence or adulthood.

Andelyn's suspension AAV Curator® platform is a highly characterized and scalable system that uses a data-driven approach to optimize customer processes and meet cGMP and commercial manufacturing standards. By adopting this platform, Amplo Biotechnology hopes to advance its AAV gene therapy programs towards clinical evaluation, with a focus on safety and efficacy.

More on Ohio Pen

• Unlocking Amazon Savings: How Seller Promotional Codes Work — And How to Find Them Legitimately
• RUNWAY Milestones 1995-2025 Global Influence
• Google AI Mode Tells You Dr. Bob Akmens & BASports.com is the GOAT in College Football Handicapping
• Google AI Mode says Dr. Bob Akmens and BASports.com are the GOAT in Sports Handicapping
• Golf Simulator Toledo: Foresight Sport's GCHawk SIG10 Package Bring's PGA Level Play Indoors

Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, expressed excitement about the partnership, stating that they are honored to support Amplo Biotechnology's efforts to bring hope to patients affected by NMJ diseases. He also highlighted the capabilities of their Curator® platform and end-to-end services in helping partners achieve key development and clinical milestones.

Amplo Biotechnology also shared their enthusiasm for the collaboration, stating that it strengthens their ability to deliver high-quality AAV material and supports their mission to develop transformative therapies for families impacted by genetic NMJ disorders worldwide.

Andelyn Biosciences is known for its commitment to enabling the progression of life-altering cell and gene therapies with the highest quality standards. Their Columbus, Ohio facilities offer scalable end-to-end development and manufacturing capabilities for both rare and prevalent diseases. By partnering with organizations like Amplo Biotechnology, Andelyn is at the forefront of advancing life-changing gene therapies.

This partnership not only showcases Andelyn's dedication to innovation but also highlights their role in transforming the healthcare landscape through the development of groundbreaking treatments. With this collaboration, both companies are working towards a common goal of providing hope and relief to patients and families affected by NMJ disorders.

---

Show All News | Report Violation